All In Biotech

NDA 020931 · Pfizer

Tikosyn

Dofetilide · Oral · Antiarrhythmic

Novel

Last checked: Nov 20, 2026Latest source record: Aug 8, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1999

Oct 1, 1999

Approved uses

1

Original approval plus efficacy supplements

Registered trials

14

3 Phase 3, 0 recruiting

FAERS reports

10,514

6,255 serious, 812 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

To minimize the risk of induced arrhythmia, patients initiated or re-initiated on TIKOSYN should be placed for a minimum of 3 days in a facility that can provide calculations of creatinine clearance, continuous electrocardiographic monitoring, and cardiac resuscitation. For detailed instructions regarding dose selection, see DOSAGE AND ADMINISTRATION .

What it is approved for

From the label in effect Apr 21, 2026.

INDICATIONS AND USAGE Maintenance of Normal Sinus Rhythm (Delay in AF/AFl Recurrence) TIKOSYN is indicated for the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation/atrial flutter [AF/AFl]) in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm. Because TIKOSYN can cause life threatening ventricular arrhythmias, it should be reserved for patients in whom atrial fibrillation/atrial flutter is highly symptomatic. In general, antiarrhythmic therapy for atrial fibrillation/atrial flutter aims to prolong the time in normal sinus rhythm. Recurrence is expected in some patients (see CLINICAL STUDIES ). Conversion of Atrial Fibrillation/Flutter TIKOSYN is indicated for the conversion of atrial fibrillation and atrial flutter to normal sinus rhythm. TIKOSYN has not been shown to be effective in patients with paroxysmal atrial fibrillation.

Mechanism: Mechanism of Action Dofetilide shows Vaughan Williams Class III antiarrhythmic activity. The mechanism of action is blockade of the cardiac ion channel carrying the rapid component of the delayed rectifier potassium current, I Kr . At concentrations covering several orders of magnitude, dofetilide blocks only I Kr with no relevant block of the other repolarizing potassium currents (e.g., I Ks , I K1 ). At clinically relevant concentrations, dofetilide has no effect on sodium channels (associated with Class I effect), adrenergic alpha-receptors, or adrenergic beta-receptors.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • TIKOSYN · DOFETILIDE 0.25MG · CAPSULE, ORAL · Prescription · TE AB
  • TIKOSYN · DOFETILIDE 0.5MG · CAPSULE, ORAL · Prescription · TE AB
  • TIKOSYN · DOFETILIDE 0.125MG · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Dofetilide" as an intervention, any sponsor and status, largest first.

All 14 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • atrial fibrillation1,071
  • drug ineffective1,035
  • dyspnoea622
  • dizziness564
  • fatigue536
  • death485
  • electrocardiogram qt prolonged447
  • headache398
  • diarrhoea330
  • malaise323
  • drug interaction298
  • nausea296

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004249
2005196
2006156
2007118
200881
2009100
2010681
2011347
2012487
2013576
2014708
2015829
2016947
2017628
2018650
2019927
2020566
2021460
2022417
2023416
2024455
2025321
2026199

Recalls

1 FDA enforcement reports for this application.

  • Dec 3, 2014 · Class II · Terminated

    Failed Tablet/Capsule Specifications: Product being recalled due to the potential presence of cracked or broken capsules.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Tikosyn (Dofetilide)

2024 spending

$663K

Beneficiaries

133

526 claims

Per beneficiary

$4,985

$10.48 per unit

View as table
YearSpending
2020$2,403,027
2021$412,298
2022$640,212
2023$789,599
2024$663,038

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 84 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.